Wall Street brokerages expect Boston Scientific Corporation (NYSE:BSX) to report earnings of $0.34 per share for the current quarter, Zacks reports. Ten analysts have issued estimates for Boston Scientific’s earnings, with the highest EPS estimate coming in at $0.35 and the lowest estimate coming in at $0.31. Boston Scientific reported earnings of $0.30 per share in the same quarter last year, which indicates a positive year over year growth rate of 13.3%. The company is expected to announce its next quarterly earnings report before the market opens on Thursday, February 1st.

According to Zacks, analysts expect that Boston Scientific will report full year earnings of $1.25 per share for the current fiscal year, with EPS estimates ranging from $1.23 to $1.26. For the next year, analysts forecast that the company will post earnings of $1.38 per share, with EPS estimates ranging from $1.34 to $1.43. Zacks’ EPS calculations are a mean average based on a survey of research analysts that cover Boston Scientific.

Boston Scientific (NYSE:BSX) last issued its earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 EPS for the quarter, hitting the consensus estimate of $0.31. The firm had revenue of $2.22 billion during the quarter, compared to analysts’ expectations of $2.21 billion. Boston Scientific had a return on equity of 23.60% and a net margin of 9.55%. Boston Scientific’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same period last year, the business earned $0.27 earnings per share.

A number of research analysts have issued reports on BSX shares. Stifel Nicolaus reissued a “buy” rating and set a $32.00 price objective on shares of Boston Scientific in a report on Monday, September 25th. SunTrust Banks reissued a “buy” rating and set a $34.00 price objective on shares of Boston Scientific in a report on Monday, October 2nd. Needham & Company LLC reissued a “buy” rating and set a $32.00 price objective on shares of Boston Scientific in a report on Tuesday, October 3rd. BMO Capital Markets reissued a “buy” rating and set a $30.00 price objective on shares of Boston Scientific in a report on Friday, October 13th. Finally, Zacks Investment Research cut Boston Scientific from a “hold” rating to a “sell” rating in a report on Monday, October 16th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $30.94.

Shares of Boston Scientific (NYSE BSX) traded up $0.65 during midday trading on Friday, hitting $25.97. The company’s stock had a trading volume of 14,115,838 shares, compared to its average volume of 10,860,000. The company has a market capitalization of $35,660.00, a PE ratio of 42.57, a PEG ratio of 1.82 and a beta of 0.96. Boston Scientific has a 12 month low of $21.95 and a 12 month high of $29.93. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.50 and a current ratio of 0.72.

In other news, insider Valley Gold Master Fund L. Sun acquired 408,006 shares of the stock in a transaction that occurred on Tuesday, November 28th. The stock was purchased at an average cost of $0.45 per share, for a total transaction of $183,602.70. Also, EVP Michael P. Phalen sold 15,835 shares of Boston Scientific stock in a transaction dated Saturday, December 29th. The stock was sold at an average price of $25.25, for a total value of $399,833.75. The disclosure for this sale can be found here. Insiders sold 82,670 shares of company stock valued at $2,196,008 over the last ninety days. 0.74% of the stock is currently owned by company insiders.

Hedge funds have recently made changes to their positions in the stock. Valeo Financial Advisors LLC acquired a new stake in Boston Scientific in the third quarter worth about $138,000. Steward Partners Investment Advisory LLC acquired a new stake in Boston Scientific in the third quarter worth about $139,000. Acrospire Investment Management LLC increased its position in Boston Scientific by 157.3% in the second quarter. Acrospire Investment Management LLC now owns 5,071 shares of the medical equipment provider’s stock worth $141,000 after purchasing an additional 3,100 shares during the period. San Francisco Sentry Investment Group CA acquired a new stake in Boston Scientific in the second quarter worth about $191,000. Finally, Ironwood Investment Counsel LLC acquired a new stake in Boston Scientific in the third quarter worth about $204,000. Hedge funds and other institutional investors own 90.36% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Zacks: Analysts Anticipate Boston Scientific Corporation (BSX) to Announce $0.34 EPS” was first posted by Marea Informative and is the property of of Marea Informative. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark laws. The legal version of this news story can be read at https://www.mareainformativa.com/2018/01/30/zacks-analysts-anticipate-boston-scientific-corporation-bsx-to-announce-0-34-eps-updated-updated-updated.html.

Boston Scientific Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Get a free copy of the Zacks research report on Boston Scientific (BSX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.